Market Cap (In USD)
1.15 Million
Revenue (In USD)
13 Thousand
Net Income (In USD)
-48.07 Million
Avg. Volume
3101.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0012-1.49
- PE
- -
- EPS
- -
- Beta Value
- 1.98951
- ISIN
- US0076244062
- CUSIP
- 007624307
- CIK
- 1100397
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Kenneth A. Berlin J.D.
- Employee Count
- -
- Website
- https://www.advaxis.com
- Ipo Date
- 2020-05-08
- Details
- Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
More Stocks
-
SCST
-
3163Browave Corporation
3163
-
CPRCompremum S.A.
CPR
-
KGH
-
TEL2-BTele2 AB (publ)
TEL2-B
-
6245
-
FNMAG
-
AREAecon Group Inc.
ARE